SCHEMBL8182060

SCHEMBL8182060

O=C1N[C@H](B(O)O)CCCCCCCCC[C@H](NCC2CCCCC2)C(=O)N2C[C@H](OC(=O)N3Cc4ccccc4C3)C[C@@H]12

nearest known ligand 0.34

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ FAP Q12884 3/20 0.34
▸ DPP4 P27487 1/20 0.34
▸ DPP8 Q6V1X1 1/20 0.34
▸ DPP9 Q86TI2 1/20 0.34
▸ DPP7 Q9UHL4 1/20 0.34
▸ NAMPT P43490 4/20 0.33
▸ GRIN2B Q13224 1/20 0.32
▸ ADAM10 O14672 1/20 0.31
▸ MMP1 P03956 1/20 0.31
▸ ERBB2 P04626 1/20 0.31
▸ KDM1A O60341 1/20 0.31
▸ MAOA P21397 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ MAPT P10636 1/20 0.31
▸ TDP1 Q9NUW8 1/20 0.31
▸ MEN1 O00255 1/20 0.30
▸ KMT2A Q03164 1/20 0.30
▸ HDAC4 P56524 1/20 0.30
▸ HDAC1 Q13547 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13336408 0.90 DPP8 (0.36) FAPDPP4DPP8DPP9DPP7
SCHEMBL8192438 0.89 FAP (0.34) FAPDPP4DPP8DPP9DPP7
SCHEMBL8190850 0.89 TAAR1 (0.34) FAPDPP4DPP8DPP9DPP7
SCHEMBL8182338 0.87 THRB (0.32) FAPDPP4DPP8DPP9DPP7
SCHEMBL8195289 0.87 MEN1 (0.34) FAPDPP4DPP8DPP9DPP7
SCHEMBL8190905 0.87 ALDH1A1 (0.32) FAPDPP4DPP8DPP9DPP7
SCHEMBL8190778 0.87 TDP1 (0.34) FAPDPP4DPP8DPP9DPP7
SCHEMBL8195302 0.87 KDM4E (0.32) FAPDPP4DPP8DPP9DPP7
SCHEMBL8187946 0.87 DPP4 (0.30) FAPDPP4DPP8DPP9DPP7
SCHEMBL8199602 0.87 NAMPT (0.36) FAPDPP4DPP8DPP9DPP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100120716-A1 MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR PHENOMIX CORPORATION (US) 2010-05-13 — — US disclosed
US-20100120716-A1 MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR PHENOMIX CORPORATION (US) 2010-05-13 — — US disclosed
WO-2008070733-A2 MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR PHENOMIX CORPORATION (US) 2008-06-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120716-A1 MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR PREP, HPN, PEPD FAP 31/4885DPP4 36/4885DPP8 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback